Fagan Nicole, Meah Nekma, York Katherine, Bokhari Laita, Fletcher Godfrey, Chen Gang, Tobin Desmond J, Messenger Andrew, Irvine Alan D, Sinclair Rodney, Wall Dmitri
School of Medicine, Trinity College Dublin, Dublin, Ireland.
Sinclair Dermatology, Melbourne, Australia.
Clin Dermatol. 2021 Jan-Feb;39(1):76-83. doi: 10.1016/j.clindermatol.2020.12.015. Epub 2020 Dec 16.
As of July 9, 2020, there were more than 12 million confirmed cases of coronavirus disease 2019 (COVID-19) across the globe, with more than 550,000 deaths. Many European countries, including Belgium, the United Kingdom, Italy, and Spain, have had the highest numbers of fatalities per capita. This indicates the potential for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus to overwhelm even the most advanced health care systems despite extreme societal interventions. Since its emergence, SARS-CoV-2 has disseminated across the globe, affecting the structure of global societies, infrastructure, and economies. Patients with alopecia are a diverse group who, for various indications, are prescribed a number of antimicrobials and antiandrogen treatments in addition to immunomodulatory therapies such as hydroxychloroquine, oral corticosteroids, and a range of broad immunosuppressants. These drugs are being scrutinized for their capacity to potentially affect SARS-CoV-2 outcomes. We examine these treatments and highlight the critical role that patient registries will play in generating real-world evidence to assess their impact on COVID-19 outcomes.
截至2020年7月9日，全球新型冠状病毒肺炎（COVID-19）确诊病例超过1200万例，死亡人数超过55万。包括比利时、英国、意大利和西班牙在内的许多欧洲国家人均死亡人数最多。这表明，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒即使在社会采取极端干预措施的情况下，仍有可能压垮最先进的医疗保健系统。自出现以来，SARS-CoV-2已在全球传播，影响着全球社会的结构、基础设施和经济。斑秃患者群体多样，除了免疫调节疗法（如羟氯喹、口服糖皮质激素和一系列广泛的免疫抑制剂）外，还因各种适应症而被开了多种抗菌药物和抗雄激素药物。这些药物因其可能影响SARS-CoV-2病情转归的能力而受到审查。我们研究了这些治疗方法，并强调了患者登记在生成真实世界证据以评估其对COVID-19病情转归的影响方面将发挥的关键作用。
